BrainStorm Cell Therapeutics Inc. has announced the U.S. Food and Drug Administration's clearance for the initiation of a Phase 3b clinical trial of NurOwn® for the treatment of amyotrophic lateral sclerosis (ALS). The trial, which was developed in agreement with the FDA's Special Protocol Assessment, is designed to enroll approximately 200 participants at leading academic medical centers. It will comprise a 24-week randomized, double-blind, placebo-controlled phase, followed by a 24-week open-label extension. The primary endpoint of the study is the change in the ALS Functional Rating Scale-Revised from baseline to week 24. The company has scheduled an investor call and webcast to discuss this development further.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.